Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.44 which represents a decrease of $-0.50 or -2.39% from the prior close of $20.94. The stock opened at $20.95 and ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar ...

Teva Pharmaceutical (NYSE:TEVA) has entered into a strategic collaboration with Klinge Biopharma and Formycon AG, for the ...

Pharmaceutical companies brace for the upcoming Trump administration. Teva Pharmaceuticals (TEVA) CEO Richard Francis joins ...

Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report) and increased ...

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

Teva (TEVA) announced that it has entered into a strategic collaboration with Klinge Biopharma and Formycon for the semi-exclusive ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Timing Trades in Teva Pharmaceutical Industries Limited American Depositary Shares TEVA can be Risky if you Don't Have ...

In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.94 which represents a decrease of $-0.55 or -2.56% from the prior close of $21.49. The stock opened at $21.27 and ...